Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Amazon’s One Medical Acquisition is Critical for Proving Subscription-Based Primary Care

Affordable and accessible healthcare is a problem that has plagued Americans for decades. For companies like Amazon, this dysfunction is a prime opportunity to further disrupt another legacy market. Amazon has announced plans to buy One Medical, a subscription-based healthcare company, for nearly $4 billion U.S. dollars. One Medical provides 24/7 on-demand virtual care coupled…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Promoted content from Amazon on MarketScale.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

Affordable and accessible healthcare is a problem that has plagued Americans for decades. For companies like Amazon, this dysfunction is a prime opportunity to further disrupt another legacy market.

Amazon has announced plans to buy One Medical, a subscription-based healthcare company, for nearly $4 billion U.S. dollars. One Medical provides 24/7 on-demand virtual care coupled with the option to get same-day and next-day in-person appointments in major cities across the U.S.

This is just the next big announcement in a string of high-profile ventures as more and more companies look to primary care as the next field for business opportunities. While it’s yet to be seen if these reimagining of primary care business models will turn into operational or patient-side savings, the need for some sort of change to our current way of administering healthcare is evident.

“It has become more and more expensive to access doctor visits, to have hospital admissions. In fact, the cost of healthcare is so expensive it puts it out of reach for many Americans,” said Melanie Musson, insurance expert with Clearsurance.com.

According to the U.S. Census Bureau, approximately 28 million Americans did not have healthcare in 2020. That number may seem small; however, it does not reflect the true reality of healthcare access. For one, it does not include Medicare or Medicaid recipients who often have limited access to care. It also does not include individuals with low-cost insurance who cannot utilize services due to high deductibles and co-payments.

The American reality is that many people cannot afford healthcare due to its high costs. This particularly affects underserved communities; low-income individuals that do not qualify for Medicare or Medicaid; and people who live in rural areas.

One of the more popular disruption models, subscription-based primary care, has captured media and investor attention. One Medical was one of the most prominent companies in this space, and now with Amazon’s purchase of the company, on-demand primary care is getting unparalleled resources to further develop and prove the concept.

“This step is a big step towards a subscription-based healthcare model. This type of model is quite different from a private insurance model or a Medicare/Medicaid type of model. It could revolutionize the access to healthcare for Americans that currently do not have access to good healthcare,” Musson said.

Faisal Khan, Senior Legal Counsel for private and public healthcare clients at Nixon Gwilt Law, agrees that Amazon’s move is a game-changer for the healthcare industry.

“Amazon’s business model, which is really defined by efficiency and personalization, is informed by vast amounts of consumer data,” Khan said.

Khan believes the trend of non-healthcare companies entering the healthcare arena will continue. And more importantly, he believes it’s a good thing and will help to expand access to healthcare for underserved populations.

“Ultimately, non-traditional players entering into the market space will exacerbate or increase the speed at which traditional providers are looking to adjust their ways of delivering care, their operations and taking advantage of opportunities to think broadly about how they could augment or innovate their care delivery systems so that they can have a greater impact on patient outcomes.”

The potential for subscription-based healthcare to improve care and patient outcomes is due to many factors. For one, it has the potential to increase communication and coordination of services. Secondly, normalizing virtual visits whenever possible lowers costs and increases patient access. Finally, it allows for the successful collection and analysis of consumer and patient data.

“Vast amounts of consumer/patient data can inform care paths, it can create new care paths and data aggregation and analytics can be used to create new patient-specific care paths and also disease-specific care plans and care paths,” Khan said.

With Amazon and One Medical at the helm of subscription-based primary care, collecting and analyzing more patient-side data, but with the level of insight of today’s online consumer, will no doubt become a part of the healthcare process. The most important puzzle piece is doing all this while serving to improve care and outcomes first and foremost, as well as reduce the nation’s bloated healthcare budget. Not only that, the acquisition is sure to open the door for more non-traditional companies to enter the healthcare delivery space while utilizing technology to bring new solutions to age-old challenges.

Amazon

Part of this channel

Amazon

Amazon's expert content for enterprise technology and commerce buyers.

Visit the channel

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended AstraZeneca and Daiichi Sankyo’s Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly is investing $6.5 billion in a Houston manufacturing facility set to open around 2030, primarily to scale production of Foundayo, its oral GLP-1 treatment. The project signals a broader shift in U.S. pharmaceutical manufacturing reshoring and underscores the supply chain challenge of forecasting demand and building capacity years in advance for breakthrough therapeutics.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain: Lilly's CEO noted that one-third of new GLP-1 pill patients are now choosing Foundayo, illustrating fast-moving market share shifts that complicate production planning years in advance
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

Waiting for perfectly clean data is stalling healthcare AI, not protecting it

Healthcare organizations often delay AI initiatives waiting for perfectly clean data, but this assumption no longer holds: reliable subsets and synthetic data allow projects to start now while data work continues in parallel. Success requires starting with business outcomes rather than technology capabilities, and embedding governance in product strategy before implementation, not after.

  • 01Waiting for 100% clean data is effectively a decision never to start; hospital AI projects can begin on reliable data subsets while quality work continues in parallel.
  • 02Frame AI decisions around business outcomes (revenue growth, cost reduction, competitive advantage, new products, or ecosystem influence) rather than asking what AI can do.
  • 03Governance should be part of product strategy before design or purchase, especially as agentic AI takes actions—such as handling many revenue-cycle denials—while routing the rest to humans.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512